Abstracts

VARIANT SELECTION, CHARACTERIZATION, AND IMPACT ON ANTIBODY SARS-CoV-2 NEUTRALIZATION

Monitoring genomic variation of SARS-CoV-2 is crucial in mitigating adaptation to the human host and developing effective treatments that safeguard global health. Bamlanivimab and etesevimab are monoclonal antibodies (mAbs) that have demonstrated potent SARS-CoV-2 neutralizing activity in both pre-clinical and clinical settings and have distinct but overlapping binding sites. Here, the selection and characterization of…

HIV WITH TRANSMITTED DRUG RESISTANCE IS DURABLY SUPPRESSED BY B/F/TAF AT WEEK 144

Two phase 3, randomized, double-blind, active-controlled studies of initial HIV-1 treatment demonstrated that bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) was non-inferior to dolutegravir/abacavir/lamivudine (DTG/ABC/3TC, Study 1489) or to DTG+F/TAF (Study 1490) through 144 weeks. In both studies, there was no emergent resistance to study drugs. Here, we describe the effect of baseline transmitted drug resistance (TDR) on treatment…

DRUG RESISTANCE DURING LOW-LEVEL HIV VIREMIA SUPPORTS LOWERING THRESHOLD FOR SWITCH

The World Health Organization (WHO) guidelines on antiretroviral therapy (ART) define the HIV-1 viral load (VL) threshold for treatment failure as 1,000 copies/mL. The SESOTHO trial, conducted in Lesotho, found that patients with persistent viremia below this threshold on first-line ART benefitted from switching to second-line ART. This pre-planned nested study assessed the prevalence of…

EVALUATION OF COMBINATIONS OF CLINICAL INTEGRASE MUTATIONS ON InSTI RESISTANCE

While major integrase strand transfer inhibitor (INSTI) resistance mutations have been identified, the effect of mutation combinations on phenotypic resistance are less clear. We identified a clinical HIV sequence with four major integrase resistance mutations, and characterized in vitro INSTI phenotypic susceptibility of all combinations thereof to deconstruct their individual and combined effects. Routine clinical…

ANALYSIS OF INTRAHOST Gag-Pol EVOLUTION WITH NOVEL SINGLE-MOLECULE SEQUENCING METHOD

Technical challenges remain in the sequencing of circulating HIV vRNA due to its high intrahost diversity. This bottleneck is particularly pronounced when interrogating long-range co-evolution, which has hampered the direct observation of genetic interactions that code for protein-protein interfaces with relevance in drug and vaccine development. To overcome the read-length limitations of NGS and the…

A MULTIPLEXED HIV DRUG RESISTANCE (DR) ASSAY TO SURVEY HIVDR MUTATIONS IN POL REGION

As the WHO universal treatment policy using dolutegravir (DTG) for HIV treatment approaches full implementation globally, a user friendly, sensitive, low-cost HIVDR assay to survey Integrase (INT) HIVDR is urgently needed. By incorporating newly designed INT primers into Thermo Fisher (TF) HIV-1 Genotyping Assay, we constructed a multiplexed assay to detect HIVDR mutations of Protease,…